Europe — EMA
Palonosetron Reig Jofre
Palonosetron, the active ingredient in Palonosetron Reig Jofre, is a 5-HT3 receptor antagonist presented as a strength/form for intravenous use.
Request sourcing
What is Palonosetron?
Palonosetron, the active ingredient in Palonosetron Reig Jofre, is a 5-HT3 receptor antagonist presented as a strength/form for intravenous use. It is used to prevent nausea and vomiting associated with chemotherapy and surgery in adult patients.
GNH USA supplies Palonosetron Reig Jofre as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.
What is Palonosetron used for?
Palonosetron is a selective 5‑HT3 receptor antagonist indicated for the following clinical situations:
- Chemotherapy‑induced nausea and vomiting (CINV): Provides a long‑lasting reduction of acute and delayed nausea and vomiting after highly emetogenic chemotherapy. - Post‑operative nausea and vomiting (PONV): Reduces the incidence of nausea and vomiting following general anesthesia. - Radiotherapy‑induced nausea and vomiting: Helps control nausea and vomiting associated with radiation treatment. - Antiemetic prophylaxis in patients receiving moderately emetogenic chemotherapy: Extends protection when used in combination with other anti‑emetics.
What are the side effects of Palonosetron?
Palonosetron may cause adverse reactions, most of which are mild to moderate in intensity.
Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel habit changes. - Fatigue: general tiredness without specific cause. - Dizziness: transient sensation of light‑headedness. - Injection site erythema: mild redness at the administration site.
Serious or Rare Side Effects: - QT interval prolongation: may affect cardiac rhythm in susceptible individuals. - Severe hypersensitivity: including anaphylaxis, angio‑edema or skin rash. - Serotonin syndrome: rare when combined with other serotonergic agents. - Cardiac arrhythmias: uncommon but reported in patients with pre‑existing cardiac disease. - Neuro‑muscular weakness: very rare neuromuscular complications.
What precautions apply to Palonosetron?
When using Palonosetron, clinicians should consider several safety aspects:
- Cardiac monitoring: patients with known QT‑prolongation risk should have ECG monitoring. - Concomitant serotonergic drugs: assess the risk of serotonin seroton t t t. - Pregnancy : - Breastfeeding : - Renal - Adjustments - Store at below 20 : keep
- Store t t
What does Palonosetron interact with?
The following g d
""""""""""""""""""""""""""""""""""""""""""""""""""""""""""
